
    
      This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 „ÄÅJAK2
      and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The
      study is a randomised,multicentre,double-blind,placebo-controlled,study.
    
  